Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. is an in vivo genome editing company developing curative genetic medicines using proprietary editing systems discovered from metagenomic science. The company focuses on advancing a small set of higher-probability programs for diseases with well-understood biology, while partnering on selected programs and enabling technologies.

−359,8 %

−348,5 %

−51,8 %

7.22

7.22

— Metagenomi Therapeutics, Inc.
%
Wholly owned genome editing programs0% Internal therapeutic programs using the company's signature gene-editing systems for specific disease targets.
Collaborative research and license programs100% Partnered programs where the company earns collaboration revenue from research, development, and licensing activities.
Genome editing platform technologies0% Proprietary editing tools, discovery capabilities, and enabling technologies used to build future medicines.
Manufacturing and process capabilities0% cGMP production of clinical-grade nucleases and mRNA to support internal and collaboration programs.

The company’s direct customers are pharmaceutical and biotechnology collaborators that license its genome editing...

  • Pharmaceutical collaboratorsprimary

    Large pharma partners that pay for access to genome editing tools, research services, and potential product rights.

  • Biotechnology partnersprimary

    Smaller biotech companies that collaborate on discovery and development using the company's editing platforms.

  • Technology and manufacturing partnerssecondary

    Licensors and CMOs that provide LNP, gRNA, DNA template, and manufacturing support for programs.

  • Future therapeutic end usersemerging

    Patients with genetic diseases targeted by the company's in vivo editing programs, once products are approved.

The company is headquartered in Emeryville, California and operates primarily from the United States...

  • •Headquartered in Emeryville, California
  • •Core operations and R&D are U.S.-based
  • •cGMP manufacturing facility is being expanded in the U.S.
  • •Third-party CMOs support gRNA and DNA template supply
  • •No disclosed country revenue split; no product sales yet

Management is prioritizing a narrower set of lead programs with the highest probability of success, focusing on disease...

01
Pipeline reprioritizationshort-term

Concentrates resources on programs with the best chance of technical and regulatory success.

02
Partnership-led developmentmedium-term

Collaborations provide non-dilutive funding, validation, and access to complementary expertise.

03
Manufacturing capability buildoutmedium-term

Internal cGMP capacity reduces dependence on third parties for critical clinical-grade materials.

The company faces the typical risks of an early-stage biotech: clinical failure, regulatory delay, and the need for...

critical

Clinical and regulatory failure

Programs may not show sufficient safety or efficacy, and approval pathways can be lengthy and uncertain.

Scope
Lead genome editing programs and future pipeline assets
Materiality
high
high

Capital dependence and dilution

The company has incurred significant losses and expects to need external funding to continue development.

Scope
Operating runway and pipeline advancement
Materiality
high
high

Collaboration dependence

Revenue and development progress rely on partners that may terminate, slow, or dispute agreements.

Scope
Ionis and other collaboration arrangements
Materiality
high
high

Third-party manufacturing and supply chain

The company relies on CMOs and suppliers for gRNA, DNA templates, and future commercial supply.

Scope
Clinical and commercial material supply
Materiality
medium
high

Intellectual property protection

Genome editing is highly competitive and difficult to defend without broad, enforceable IP.

Scope
Platform technologies and therapeutic candidates
Materiality
high
high

Safety and post-approval obligations

Adverse events could trigger REMS, label restrictions, litigation, or loss of market acceptance.

Scope
Any approved genome editing product
Materiality
medium
Collaboration revenue recognition
Can create uneven quarterly revenue and affect comparability
Stock-based compensation
Increases operating losses without immediate cash outflow
Lease accounting
Creates right-of-use assets and lease liabilities that affect leverage metrics
Deferred tax assets and uncertain tax positions
Can lead to valuation allowances and earnings volatility

CRISPR Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

SANGAMO THERAPEUTICS, INC

SGMOQ · Biological Products, (No Diagnostic Substances)

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Monte Rosa Therapeutics, Inc.

GLUE · Biological Products, (No Diagnostic Substances)

: 28/04/2026